2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u v [w] x y z

Abstract Number: 2547

Weekly Subcutaneous Abatacept Confers Comparable Onset of Treatment Response and Magnitude of Efficacy Improvement Over 6 Months When Administered with or without an Intravenous Abatacept Loading Dose
Abstract Number: 2533

Weight Loss Is Associated with Structure Modification in Subjects with Radiographic Osteoarthritis of the Knee: Data From the Osteoarthritis Initiative
Abstract Number: 2375

WHAT Affects the Quality of Life in Patients with BEHCET’S Disease?
Abstract Number: 1134

What Are the Levels of Physical Activities and Their Associations with Quality of Life in Patients with Symptomatic Hip and/or Knee Osteoarthritis?
Abstract Number: 1995

What Are the Most Clinically Relevant and Feasible Pragmatic Osteoporosis Clinical Trial Designs?
Abstract Number: 1024

What Constitutes the Characteristic Fat Lesion On MRI of the Sacroiliac Joints in Early Spondyloarthritis?
Abstract Number: 1719

What Do Patients Put up with for the Benefit They Get From Methotrexate?
Abstract Number: 1924

What Do Patients with Polmyalgia Rheumatica Mean When They Describe Stiffness? A Qualitative Study
Abstract Number: 1902

What Factors Are Associated with Target Serum Urate Concentrations in Patients with Gout?
Abstract Number: 862

What Is the Impact of a Transition Program On Adolescents with Juvenile Idiopathic Arthritis and Their Parents ?
Abstract Number: 499

What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Abstract Number: 1557

What Percentage of Postmenopausal Women Younger Than Age 65 Years Have Low Bone Mineral Density At a Family Health Center?
Abstract Number: 1560

What Will Determine Adherence to Pharmaceutical Treatment for Rheumatoid Arthritis? A Systematic Review
Abstract Number: 1641

When Can Biological Therapy Be Resumed in Patients with Rheumatic Conditions Who Develop Tuberculosis Infection During Tumour Necrosis Factors Antagonists Therapy? Study Based On the Biobadaser Data Registry
Abstract Number: 1837

Which Rheumatoid Arthritis, Ankylosing Spondylitis and Juvenile Idiopathic Arthritis Patients Initiate Anti-TNFá Therapy?
Abstract Number: 1099

Whole Blood Lead Is Associated with Symptoms, but Not Radiographic Osteoarthritis, in Multiple Joint Sites: The Johnston County Osteoarthritis Project
Abstract Number: 2000

Whole Body Magnetic Resonance Imaging in Evaluation of Enthesitis in Spondyloarthropathy
Abstract Number: 751

Whole Transcriptome Analysis in Erdheim-Chester Disease: A Multicenter Collaborative Study of 58 Patients
Abstract Number: 2532

Whole Transcriptome Analysis in Relapsing Polychondritis: A Single-Center Analysis of 35 Patients
Abstract Number: 1041

Whole-Body Magnetic Resonance Imaging – A New Diagnostic Tool in the Assessment of Activity in Juvenile Dermatomyositis Patients?
Abstract Number: 1617

Whole-Body Magnetic Resonance Imaging of Disease Manifestations in Axial and Peripheral Joints and Entheses in Rheumatoid Arthritis Patients
Abstract Number: 1579

Why Do We Need to Pilot Interventions? Essential Refinements Identified During Pilots of a Fatigue Intervention
Abstract Number: 2544

Widening Gap Between Cardiovascular Specific Mortality in Patients with Inflammatory Polyarthritis Compared to the General Population?
Abstract Number: 864

Will I Waste Your Time? Delays in Help-Seeking for RA Flares
Abstract Number: 1498

Wisp-1 Neutralization Reduces Gvhd-Induced Skin Fibrosis by Altering TSLP-OX40L Axis-Dependent Th2 Responses
Abstract Number: 1625

With Chlamydia Infection the Macrophage Serves As Gate-Keeper for Dissemination and Induction of Host Immunity
Abstract Number: 543

Wnt Pathway Inhibitors in Patients with Psoriatic and Rheumatoid Arthritis Treated with Anti-TNF Therapy
Abstract Number: 1797

Wnt Signaling Pathway Status, Determined by Serum Dkk-1 and R-Spondin 1 Levels, in Rheumatoid Arthritis and Ankylosing Spondylitis
Abstract Number: 1429

Women with Systemic Lupus Erythematosus (SLE) May Have Different Predictors of Risk for Progression of Aorta Calcium (AS) Than Women without SLE
Abstract Number: 1430

Women with Systemic Lupus Erythematosus (SLE) May Have Different Predictors of Risk for Progression of Coronary Artery Calcium (CAC)Than Women without SLE
Abstract Number: 1825

Work Disability and Work Limitations in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Are Equal and Increase with Comorbidities
Abstract Number: 945

Work Loss in Systemic Lupus Erythematosus, the General Public, and Other Chronic Conditions
Abstract Number: 2409

Work Productivity in a Population Based Cohort of Patients with Spondyloarthritis
Abstract Number: 1879

Work Related Injuries Causing or Aggravating Fibromyalgia in the Medicolegal Arena: A Jurisprudential Analysis
Abstract Number: 1465

World Health Organization Classification of Pulmonary Hypertension and Survival in Systemic Sclerosis Patients in the Pharos Cohort

Jump to: View All • a b c d e f g h i j k l m n o p q r s t u v [w] x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].